• Ribociclib pH Shifts: A QbD Interaction Assessment

  2026-09-23

  A Quality by Design analytical method and biorelevant micro-dissolution study examined whether pH shifts associated with acid-reducing therapy could materially affect ribociclib succinate solubility. Although measured solubility decreased after the modeled shifts, the authors concluded that the changes did not indicate a significant effect under the tested conditions, while emphasizing the value of dynamic in vitro assessment.

• Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor

  2026-09-23

  A high-throughput biochemical study identified Merbromin as a selective mixed-type inhibitor of the SARS-CoV-2 main protease, 3CLpro. Its combination of activity-based screening, kinetic analysis, binding measurements, and molecular docking provides a useful framework for evaluating repurposed compounds while also defining the limits of biochemical evidence.

• Baicalin methyl ester: Assay Design Guide

  2026-09-22

  A scenario-based guide to using Baicalin methyl ester (SKU N2884) in cell viability, proliferation, and LPS-induced intestinal barrier damage research. It covers concentration selection, solvent compatibility, controls, mechanistic readouts, and practical product-selection criteria supported by product data and literature.

• LAG-3–TCR Proximity in T Cell Suppression

  2026-09-22

  A 2025 Cell study shows that LAG-3-mediated inhibition depends not only on MHC class II binding but also on spatial proximity to the T cell receptor. By linking LAG-3 and the TCR with an Fc-attenuated bispecific antibody, the authors achieved broad T cell suppression and reduced autoimmune disease in mouse models, while identifying a CD3ε/Lck signaling mechanism.

• Mavorixafor in WHIM Syndrome: Phase 3 Evidence

  2026-09-21

  The reference commentary highlights a placebo-controlled phase 3 trial showing that oral CXCR4 inhibition with mavorixafor can extend neutrophil and lymphocyte availability and reduce infections in WHIM syndrome. Its main contribution is the translation of disease mechanism into a practical, sustained treatment strategy while also identifying unresolved questions about long-term safety, immune restoration, and cancer risk.

• 8-Chloroadenosine: Reliable RNA Assays

  2026-09-21

  A practical, scenario-driven guide to using 8-Chloroadenosine (SKU B7667) in RNA synthesis, viability, proliferation, and cytotoxicity workflows. It addresses stock preparation, dose–time design, interpretation of IL-6 and lncRNA experiments, and evidence-based product selection.

• 6C Medium Preserves Mouse Corneal Epithelial Growth

  2026-09-20

  An et al. developed a serum-free, feeder-free 6C culture system that combines six pathway modulators with keratinocyte calcium to prolong mouse corneal epithelial cell proliferative activity. By limiting epithelial-to-mesenchymal changes while retaining progenitor-associated markers, the approach improves generation of epithelial populations for wound-healing and regenerative-medicine studies.

• Phillygenin and Signaling in Diabetic Nephropathy

  2026-09-19

  The reference study identifies phillygenin as a potential intervention for diabetic nephropathy and links its protective effects to coordinated suppression of TLR4/MyD88/NF-κB inflammation and restoration of PI3K/AKT/GSK3β signaling. By combining high-glucose podocyte experiments, RNA sequencing, biochemical assays, and db/db mouse studies, it provides a preclinical framework for connecting reduced inflammation and apoptosis with improved renal function.

• Boc-D-FMK Workflows for Apoptosis Research

  2026-09-18

  Boc-D-FMK is a cell-permeable pan-caspase inhibitor for separating caspase-dependent apoptosis from upstream inflammatory signaling. This practical guide combines product-supported treatment conditions with renal, hepatic, and fibrosis-oriented assay strategies, while clearly distinguishing validated use from hypothesis-generating applications.

• Gallein and the Next Frontier of GPCR Translation

  2026-09-18

  Gallein offers translational researchers a way to interrogate G protein βγ-dependent signaling across cancer, immunity, cardiac inflammation, and emerging metabolic biology. By connecting validated preclinical applications with the lactate–GPR81/FARP1–RAC1 axis, this article outlines a rigorous strategy for testing whether Gβγ signaling contributes to insulin-independent glucose uptake without overstating current evidence.

• Protease Inhibitor Cocktail: EDTA-Free Workflow

  2026-09-17

  Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) helps limit endogenous proteolysis during protein extraction and sample preparation for Western blotting, co-immunoprecipitation, pull-downs, and phosphorylation-sensitive assays. It should not be treated as a complete phosphatase inhibitor system or used without compatibility testing in DMSO-sensitive assays and workflows that intentionally measure protease activity.

• HyperScript™ RT SuperMix for qPCR: Assay Logic

  2026-09-17

  HyperScript™ RT SuperMix for qPCR supports reproducible cDNA synthesis for complex or scarce RNA. This article uses a pedalitin–NAFLD study to show how reverse-transcription design influences gene expression interpretation and assay confidence.

• (R)-MG132: A Better Control for Metabolic Mechanisms

  2026-09-16

  A rigorous guide to using (R)-MG132, the functionally inactive MG-132 enantiomer, to separate proteasome-dependent effects from off-target stress in cancer metabolism and mechanistic studies.

• Dual-Action p38α Inhibition and Dephosphorylation

  2026-09-16

  The reference preprint shows that selected kinase inhibitors can do more than suppress p38α catalytic activity: they can also expose the activation-loop phosphothreonine to the phosphatase WIP1 and accelerate dephosphorylation. Its structural and biochemical framework provides a mechanistic basis for designing inhibitors that combine kinase blockade with phosphatase-facilitated pathway shutdown.

• Ceftolozane/Tazobactam: Evidence and Mechanism

  2026-09-15

  The reference review presents ceftolozane/tazobactam as an antipseudomonal cephalosporin and beta-lactamase inhibitor combination designed to address important resistance mechanisms in gram-negative infections. Its most useful contributions are the integration of PBP pharmacology, resistance biology, pharmacokinetics, pharmacodynamics, clinical evidence, and safety considerations into a framework for interpreting antibacterial research.

7825 records 1/522 page Next 12345 下5页 Last page